DNA vaccines: Vector design, delivery, and antigen presentation

Feltquate, David

doi:10.1002/(sici)1097-4644(1998)72:30/31+<304::aid-jcb37>3.0.co;2-w

Cited by 16 publications

(7 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This indicated that the new construct pcDNAintpp65, expressing the native gene of CMVpp65, elicits CTL activity in the transgenic Kb mouse and that this is specific for the minimal cytotoxic epitope of CMVpp65 previously described for the HLA A*0201, namely p 495−503 (NLVPMVATV) [27]. However, without using cardiotoxin or similar products that enhance the efficiency of DNA expression in muscle, only 50–60% of the mice responded to the immunization, which has been reported previously [35, 36].…”

Section: Resultssupporting

confidence: 60%

Kinase‐Deficient CMVpp65 Triggers a CMVpp65 Specific T‐Cell Immune Response in HLA‐A*0201.K^b Transgenic Mice after DNA Immunization

Gallez-Hawkins

Lomeli

et al. 2002

Scand J Immunol

View full text Add to dashboard Cite

CMVpp65, a candidate component of human cytomegalovirus (CMV) vaccines, has phosphokinase (PK) activity that could affect vaccine safety. A mutated form of CMVpp65 substituting asparagine for lysine at the adenosine triphosphate (ATP)‐binding site (CMVpp65mII) is kinase‐deficient. Using DNA immunizations in a transgenic human leucocyte antigen (HLA)A*0201.Kb mouse model, the mutated CMVpp65 induced cytotoxic T lymphocytes (CTL) immunity similarly to native CMVpp65. Murine CTL lines generated from these immunizations killed human cells either after sensitization with CMVpp65‐specific peptides or after infection with either CMV‐Towne strain or rvac‐pp65. It is proposed that CMVpp65mII be evaluated in candidate vaccines for CMV.

show abstract

Section: Resultssupporting

confidence: 60%

Kinase‐Deficient CMVpp65 Triggers a CMVpp65 Specific T‐Cell Immune Response in HLA‐A*0201.K^b Transgenic Mice after DNA Immunization

Gallez-Hawkins

Lomeli

et al. 2002

Scand J Immunol

View full text Add to dashboard Cite

show abstract

“…5 The cytomegalovirus (CMV) promoter is considered to be one of the strongest promoters for driving the expression of genes encoded by DNA vaccines in vivo. 6 Many studies have showed the therapeutic efficacy of virus promoter-driven DNA vaccines in preclinical animal models. For example, our previous study showed that CMV promoter-driven cDNA encoding the extracellular domain of the human HER-2/neu gene had a therapeutic effect on established HER-2/neu-expressing tumors.…”

Section: Introductionsupporting

confidence: 58%

An HDAC inhibitor enhances the antitumor activity of a CMV promoter-driven DNA vaccine

Lai

et al. 2009

Cancer Gene Ther

View full text Add to dashboard Cite

The cytomegalovirus (CMV) promoter is considered to be one of the strongest promoters for driving the in vivo expression of genes encoded by DNA vaccines. However, the efficacy of DNA vaccines has so far been disappointing (particularly in humans), and this might be explained in part by histone deacetylase (HDAC)-mediated chromatin condensation. Hence, we sought to investigate whether increasing the expression of DNA vaccine antigens with the HDAC inhibitor OSU-HDAC42 would enhance the efficacy of DNA vaccines in vivo. A luciferase assay was used to determine the effects of OSU-HDAC42 on CMV promoter-driven DNA plasmids in vitro and in vivo. Three HDAC inhibitors were able to activate expression from the CMV promoter in NIH3T3 cells and MBT-2 bladder cancer cells. The expression of luciferase was significantly enhanced by co-administration of pCMV-luciferase and OSU-HDAC42 in mice. To explore whether OSU-HDAC42 could enhance the specific antitumor activity of a neu DNA vaccine driven by the CMV promoter, we evaluated therapeutic effects and immune responses in a mouse tumor natively overexpressing HER2/neu. Mice receiving OSU-HDAC42 in combination with the CMV-promoter neu DNA vaccine exhibited stronger antitumor effects than mice given the DNA vaccine only. In addition, a correlation between the antitumor effects and the specific cellular immune responses was observed in the mice receiving the DNA vaccine and OSU-HDAC42.

show abstract

“…The first vectors used for DNA vaccination were bacterial plasmids, developed originally for the in vitro expression of foreign protein in mammalian cells. 25 A plasmid contains a prokaryotic replication origin that allows high-yield production in bacteria, and an antibiotic resistance gene for selective growing. The transcriptional unit carries a viral promoter that may lead to constitutive expression in a wide variety of cells.…”

Section: Dna Vaccine An Overviewmentioning

confidence: 99%

“…The use of nanoparticles (NP) for vaccine delivery is one of them which have been applied for delivery of a variety of existing and potential vaccines recently. [23][24][25] Below, we will discuss different aspects of the use of nanoparticles for effective delivery of DNA vaccines.…”

Section: Introductionmentioning

confidence: 99%

DNA Mediated Vaccines Delivery Through Nanoparticles

Shah¹,

Ali²,

Rostami³

et al. 2015

j nanosci nanotechnol

View full text Add to dashboard Cite

Vaccination has led to the eradication of those diseases which had once claimed millions of lives worldwide; however, it is accompanied with a number of dis-advantages especially safety issues until the entry of DNA vaccines. The DNA vaccines have been emerged as the best remedy for problematic diseases being capable of producing humoral and cellular immune responses as well as the safest vaccines so far. However, the magnitude of immune responses produced in primates is lower than that in experimental animals. There are several reasons described theoretically for this limited efficacy and a number of novel approaches have been applied to boost their immune responses, e.g., use of more efficient promoters and coding optimization, addition of traditional or genetic adjuvants, electroporation, intradermal delivery and various prime-boost strategies. One of these strategies is controlled antigen administration of plasmid DNA through microspheres and nanoparticles. This approach is accompanied with a number of advantages to overcome the limitations of traditional delivery systems in terms of stability, solubility and pharmacology. Furthermore, the surface structure of a virus highly resembles with a nanoparticle because of their geometrical regularities and nanoscale dimensions; therefore, the engineering of nanoparticles is based upon principles of natural virus attack which will be the best tool for vaccination. There is evidence that these immune responses can be augmented by properly structured nanosized particles (nanoparticles) that may avoid DNA degradation and facilitate targeted delivery to antigen presenting cells. Adsorption, formulation or encapsulation with particles has been found to stabilize DNA formulations. The use of nanoparticles for DNA vaccine delivery is a platform technology and has been applied for delivery of a variety of existing and potential vaccines successfully.

show abstract

DNA vaccines: Vector design, delivery, and antigen presentation

Cited by 16 publications

References 38 publications

Kinase‐Deficient CMVpp65 Triggers a CMVpp65 Specific T‐Cell Immune Response in HLA‐A*0201.K^b Transgenic Mice after DNA Immunization

Kinase‐Deficient CMVpp65 Triggers a CMVpp65 Specific T‐Cell Immune Response in HLA‐A*0201.K^b Transgenic Mice after DNA Immunization

An HDAC inhibitor enhances the antitumor activity of a CMV promoter-driven DNA vaccine

DNA Mediated Vaccines Delivery Through Nanoparticles

Contact Info

Product

Resources

About

DNA vaccines: Vector design, delivery, and antigen presentation

Cited by 16 publications

References 38 publications

Kinase‐Deficient CMVpp65 Triggers a CMVpp65 Specific T‐Cell Immune Response in HLA‐A*0201.Kb Transgenic Mice after DNA Immunization

Kinase‐Deficient CMVpp65 Triggers a CMVpp65 Specific T‐Cell Immune Response in HLA‐A*0201.Kb Transgenic Mice after DNA Immunization

An HDAC inhibitor enhances the antitumor activity of a CMV promoter-driven DNA vaccine

DNA Mediated Vaccines Delivery Through Nanoparticles

Contact Info

Product

Resources

About

Kinase‐Deficient CMVpp65 Triggers a CMVpp65 Specific T‐Cell Immune Response in HLA‐A*0201.K^b Transgenic Mice after DNA Immunization

Kinase‐Deficient CMVpp65 Triggers a CMVpp65 Specific T‐Cell Immune Response in HLA‐A*0201.K^b Transgenic Mice after DNA Immunization